Genmab A/S (NASDAQ:GMAB) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Genmab A/S (NASDAQ:GMAB) from a neutral rating to an overweight rating in a report published on Monday, Marketbeat reports.

A number of other equities research analysts also recently weighed in on GMAB. Morgan Stanley set a $42.00 price target on shares of Genmab A/S in a research report on Tuesday, October 20th. HC Wainwright increased their price target on Genmab A/S from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Truist Financial increased their price target on Genmab A/S from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and raised their price objective for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Finally, Guggenheim lifted their price objective on Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.39.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $57.29 on Monday. Genmab A/S has a 52 week low of $23.62 and a 52 week high of $59.97. The firm has a market cap of $35.75 billion, a price-to-earnings ratio of 45.11, a P/E/G ratio of 2.01 and a beta of 0.81. The firm’s 50-day simple moving average is $36.20 and its 200 day simple moving average is $30.36. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. As a group, sell-side analysts predict that Genmab A/S will post 1.22 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Genmab A/S by 46.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,692 shares of the company’s stock worth $629,000 after acquiring an additional 5,615 shares during the period. Park Avenue Securities LLC increased its stake in Genmab A/S by 2.4% in the third quarter. Park Avenue Securities LLC now owns 11,258 shares of the company’s stock valued at $402,000 after acquiring an additional 265 shares during the last quarter. Signaturefd LLC increased its stake in Genmab A/S by 8.5% in the third quarter. Signaturefd LLC now owns 17,842 shares of the company’s stock valued at $636,000 after acquiring an additional 1,400 shares during the last quarter. Quadrant Capital Group LLC increased its stake in Genmab A/S by 3.5% in the third quarter. Quadrant Capital Group LLC now owns 23,243 shares of the company’s stock valued at $850,000 after acquiring an additional 786 shares during the last quarter. Finally, Capital Square LLC acquired a new position in Genmab A/S during the third quarter valued at approximately $219,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that the Phase 3 LiGeR-HN1 trial met both primary endpoints in first-line, PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. Petosemtamab combined with Merck’s pembrolizumab reduced the risk of death by 50% versus pembrolizumab alone, with a statistically significant improvement in overall survival and objective response rate, regardless of patients’ HPV status. Genmab Phase 3 trial announcement
• Positive Sentiment: The results support expectations that petosemtamab could become a meaningful commercial product and potentially establish a new treatment standard. Analysts described the results as a significant “hat trick,” while reports highlighted the drug’s potential in combination with Keytruda. Barron’s report on Genmab’s record high
• Positive Sentiment: JPMorgan upgraded its rating on GMAB, and TD Cowen said the stock could rise, adding to the positive analyst sentiment. Heavy call-option activity also indicates strong speculative interest following the clinical announcement. JPMorgan rating upgrade
• Neutral Sentiment: Genmab plans to discuss the results with global regulators and submit the full dataset for presentation at a future medical meeting. Investors still lack the complete efficacy and safety details, and regulatory approval and commercialization remain ahead. Genmab Phase III data discussion

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.